Related Experiment Videos
Novel therapies for renal cell carcinoma
M Fishman1, J Seigne, S Antonia
1H Lee Moffitt Cancer Center & Research Institute, University of South Florida, Interdisciplinary Oncology Program, 12902 Magnolia Dr., Tampa, FL 33612, USA.
Abstract:
Metastatic renal cell cancer remains a disease which is difficult to treat medically. Prognosis often depends more on intrinsic disease features than on treatment choices. In this review, we examine novel therapies and scientific directions surrounding the RCC treatment problem. Reports relating chromosomal aberrations and of comparative gene expression analyses relating to RCC, are reviewed briefly. The central role of the von Hippel Lindau protein in clear cell RCC pathogenesis is evident. The limited contribution of conventional cytotoxic chemotherapy is mentioned. Some clinically applied agents whose clinical results are highlighted include 5-FU, retinoids, thalidomide, razoxane and IL-12. Features of the pathophysiology of von Hippel Lindau protein are described, with attention to potential novel therapies targeting HIF-1alpha, VEGF, TGF-beta1 and TGF-alpha pathways. Immunotherapy is being explored in many angles. Most basic are cytokine therapies incorporating new IL-2 and IFN-alpha schedules. Newer cytokine-based drugs include pegylated forms and IL-12. Allogeneic mini-transplantation has generated much interest. Tumour-associated antigens are being used to direct therapy using both identified and non-identified epitopes. A variety of tumour-cell vaccine and dendritic-cell vaccine clinical approaches are discussed. Finally, nephrectomy for known metastatic disease has been demonstrated to be helpful in retrospective and now prospective trials. Resection of metastases is also discussed. We are optimistic that the further clinical development among these novel therapies will improve the outlook for metastatic RCC.
Insights
Metastatic renal cell cancer (RCC) treatment is challenging. This review explores novel therapies targeting pathways like VEGF and immunotherapy, offering hope for improved patient outcomes.
Area of Science:
- Oncology
- Nephrology
- Genetics
Background:
- Metastatic renal cell cancer (RCC) presents significant treatment challenges.
- Prognosis is often dictated by intrinsic disease characteristics rather than therapeutic interventions.
- The von Hippel-Lindau (VHL) protein plays a crucial role in clear cell RCC pathogenesis.
Purpose of the Study:
- To review novel therapies and scientific directions for treating metastatic RCC.
- To examine emerging treatment strategies beyond conventional chemotherapy.
- To highlight potential therapeutic targets and immunotherapeutic approaches.
Main Methods:
- Review of existing literature on chromosomal aberrations and gene expression in RCC.
- Analysis of clinical results for agents like 5-FU, retinoids, thalidomide, razoxane, and IL-12.
- Exploration of novel therapeutic pathways including HIF-1alpha, VEGF, TGF-beta1, and TGF-alpha.
- Discussion of various immunotherapy strategies, including cytokine therapy, vaccines, and allogeneic mini-transplantation.
- Evaluation of the role of nephrectomy and metastasis resection in managing metastatic RCC.
Main Results:
- Conventional cytotoxic chemotherapy has limited efficacy in metastatic RCC.
- Several agents like 5-FU, retinoids, thalidomide, razoxane, and IL-12 have shown clinical activity.
- Targeting pathways such as HIF-1alpha and VEGF shows promise.
- Immunotherapy, including cytokine therapy and vaccines, is a rapidly developing area.
- Nephrectomy and resection of metastases can be beneficial in select cases.
Conclusions:
- Novel therapies targeting specific molecular pathways and immunotherapy hold significant promise for improving metastatic RCC treatment.
- Further clinical development of these innovative approaches is crucial for enhancing patient prognosis.
- A multi-faceted strategy combining targeted therapies, immunotherapy, and potentially surgery may offer the best outlook for metastatic RCC patients.